Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02669511 | PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | completed | Phase 2 | 21 | PIQUR Therapeutics AGINDUSTRY | 0 | Jul 9, 2019 | clinicaltrials |
| NCT03127020 | Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients | completed | Phase 2 | 9 | PIQUR Therapeutics AGINDUSTRY | 1 | Jun 28, 2019 | clinicaltrials |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas |
| completed |
| Phase 1 / Phase 2 |
| 61 |
| Pharmacyclics LLC.INDUSTRY |
| 1 |
| Jun 27, 2019 |
| clinicaltrials |
| NCT02188537 | Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma | completed | Phase 2 | 34 | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT02176213 | Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 35 | Ajai ChariOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00153920 | Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma | completed | Phase 2 | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT01008462 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | completed | Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT01159574 | Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma | completed | Phase 2 | 121 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT00916058 | Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 57 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01002755 | Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT00067002 | Randomized Double Cord Blood Transplant Study | completed | Phase 2 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT01517724 | Bortezomib Consolidation Trial(BCT) | completed | Phase 2 | 40 | University College, LondonOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT01980654 | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | completed | Phase 2 | 80 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01246063 | Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01521611 | Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy | completed | Phase 1 / Phase 2 | 62 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02632786 | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis(PRONTO) | completed | Phase 2 | 129 | Prothena Biosciences Ltd.INDUSTRY | 10 | Apr 5, 2019 | clinicaltrials |
| NCT00802113 | Autologous and Allogeneic Transplant for Relapsed Lymphoma | completed | Phase 1 / Phase 2 | 30 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00439465 | Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma | completed | Phase 2 | 23 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT01383928 | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2019 | clinicaltrials |
| NCT00807599 | Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L | completed | Phase 2 | 67 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01481194 | ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma(ACVDL) | completed | Phase 2 | 35 | Vejle HospitalOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT01790737 | First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02(FMG-MM02) | completed | Phase 2 | 80 | Kuopio University HospitalOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT00943319 | Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 50 | University of ChicagoOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT02275403 | Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma(ACUFOCIN) | completed | Phase 2 | 120 | The Christie NHS Foundation TrustOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT02566265 | Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients(SHIVERING 2) | completed | Phase 2 | 122 | Yale UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01408563 | Reduced Intensity Double Umbilical Cord Blood Transplantation | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | completed | Phase 2 | 279 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01349569 | Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission | completed | Phase 2 | 19 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01720264 | Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | completed | Phase 2 | 15 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT03794167 | BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma(CISL) | completed | Phase 2 | 75 | Soonchunhyang University HospitalOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT02391116 | Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 67 | BayerINDUSTRY | 10 | Jan 4, 2019 | clinicaltrials |
| NCT03792815 | Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)(BME) | completed | Phase 2 | 51 | Soonchunhyang University HospitalOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01686321 | Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma(B-R-ENDA) | completed | Phase 2 | 68 | University of GöttingenOTHER | 1 | Dec 31, 2018 | clinicaltrials |
| NCT01470196 | Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia(CaRD) | completed | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01306643 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | completed | Phase 1 / Phase 2 | 18 | Gilead SciencesINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00038025 | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT00709592 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | completed | Phase 2 | 42 | Virginia Commonwealth UniversityOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT01698801 | A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 26 | CelgeneINDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01039025 | TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00475644 | A Study of Enzastaurin in Participants With Follicular Lymphoma | completed | Phase 2 | 66 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 5, 2018 | clinicaltrials |
| NCT01133158 | R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial | completed | Phase 2 | 61 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT01965119 | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma(JAK2) | completed | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00038090 | Thalidomide-Dexamethasone for Multiple Myeloma | completed | Phase 2 / Phase 3 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01782963 | Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)(RVD Lite) | completed | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038545 | A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2019source: clinicaltrials